Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals (ANEB) showed zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating a stable recent period on the compliance front. However, low signal in a short window does not mean low risk—biotech companies face ongoing dilution pressures, financing dependencies, and regulatory uncertainties that may not surface in quarterly snapshots. The full $49 Report extends analysis to 12 months, calculates dilution risk scores, maps financing history, and flags AI-detected risk signals across SEC filings and market activity. This deeper context reveals vulnerabilities that 90-day snapshots miss.